OBJECTIVE: To examine the measurement properties of and comparability between the English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) in breast cancer patients in Singapore. METHODS: This is an observational study of 269 patients. Known-group validity and responsiveness of the EQ-5D utility index and visual analog scale (VAS) were assessed in relation to various clinical characteristics and longitudinal change in performance status, respectively. Convergent and divergent validity was examined by correlation coefficients between the EQ-5D and a breast cancer-specific instrument. Test-retest reliability was evaluated. The two language versions were compared by multiple regression analyses. RESULTS: For both English and Chinese versions, the EQ-5D utility index and VAS demonstrated known-group validity and convergent and divergent validity, and presented sufficient test-retest reliability (intraclass correlation = 0.72 to 0.83). The English version was responsive to changes in performance status. The Chinese version was responsive to decline in performance status, but there was no conclusive evidence about its responsiveness to improvement in performance status. In the comparison analyses of the utility index and VAS between the two language versions, borderline results were obtained, and equivalence cannot be definitely confirmed. CONCLUSION: The five-level EQ-5D is valid, responsive, and reliable in assessing health outcome of breast cancer patients. The English and Chinese versions provide comparable measurement results.
OBJECTIVE: To examine the measurement properties of and comparability between the English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) in breast cancerpatients in Singapore. METHODS: This is an observational study of 269 patients. Known-group validity and responsiveness of the EQ-5D utility index and visual analog scale (VAS) were assessed in relation to various clinical characteristics and longitudinal change in performance status, respectively. Convergent and divergent validity was examined by correlation coefficients between the EQ-5D and a breast cancer-specific instrument. Test-retest reliability was evaluated. The two language versions were compared by multiple regression analyses. RESULTS: For both English and Chinese versions, the EQ-5D utility index and VAS demonstrated known-group validity and convergent and divergent validity, and presented sufficient test-retest reliability (intraclass correlation = 0.72 to 0.83). The English version was responsive to changes in performance status. The Chinese version was responsive to decline in performance status, but there was no conclusive evidence about its responsiveness to improvement in performance status. In the comparison analyses of the utility index and VAS between the two language versions, borderline results were obtained, and equivalence cannot be definitely confirmed. CONCLUSION: The five-level EQ-5D is valid, responsive, and reliable in assessing health outcome of breast cancerpatients. The English and Chinese versions provide comparable measurement results.
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Garry R Barton; Tracey H Sach; Claire Jenkinson; Anthony J Avery; Michael Doherty; Kenneth R Muir Journal: Health Qual Life Outcomes Date: 2008-07-14 Impact factor: 3.186
Authors: Chun Fan Lee; Nan Luo; Raymond Ng; Nan Soon Wong; Yoon Sim Yap; Soo Kien Lo; Whay Kuang Chia; Alethea Yee; Lalit Krishna; Celest Wong; Cynthia Goh; Yin Bun Cheung Journal: Qual Life Res Date: 2012-10-11 Impact factor: 4.147
Authors: Amaia Bilbao; Lidia García-Pérez; Juan Carlos Arenaza; Isidoro García; Gloria Ariza-Cardiel; Elisa Trujillo-Martín; Maria João Forjaz; Jesús Martín-Fernández Journal: Qual Life Res Date: 2018-07-05 Impact factor: 4.147
Authors: Seon-Ha Kim; Min-Woo Jo; Jong-Won Lee; Hyeon-Jeong Lee; Jong Kyung Kim Journal: Health Qual Life Outcomes Date: 2015-12-23 Impact factor: 3.186